Novartis CEO Vas Narasimhan says COVID-19 makes valuing takeover targets tougher
Narasimhan, a U.S. citizen who took over two years ago as CEO, acknowledged disappointment that Novartis’ existing medicines had not proven more useful against COVID-19. (Reuters photo) Swiss drugmaker Novartis AG has financial firepower for acquisitions even with net debt of $26 billion, though the COVID-19 pandemic has made it more difficult to value takeover … Read more